GLOMERULONEPHRITIS, IGA
Clinical trials for GLOMERULONEPHRITIS, IGA explained in plain language.
Never miss a new study
Get alerted when new GLOMERULONEPHRITIS, IGA trials appear
Sign up with your email to follow new studies for GLOMERULONEPHRITIS, IGA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: Zigakibart's Long-Term safety under study
Disease control Recruiting nowThis study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug shows promise for kidney disease patients
Disease control Recruiting nowThis study tests a drug called sparsentan in 24 adults with IgA nephropathy, a kidney disease. Some participants are newly diagnosed, others have the disease return after a kidney transplant. The goal is to see if sparsentan can reduce protein in the urine, a sign of kidney damag…
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE2 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to halt kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests iptacopan, an oral drug, in 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to see if the drug reduces signs of inflammation and damage over 9 months. The goal is to understand if iptacopan can slow disease pro…
Matched conditions: GLOMERULONEPHRITIS, IGA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC